INCY
$INCY
Incyte Corporation
Biopharmaceutical company focused on oncology and inflammation with Jakafi as lead drug.
Healthcare$96.88
-0.03 (-0.03%)
Day Range$96.34 - $97.60
Prev Close$96.91
Analyst Rating
Buy
16 Buy / 16 Hold / 1 Sell
Subscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
INCY: Clinical Wins and Partnership, Valuation Questioned
Incyte ($INCY) posted positive Phase 3 povorcitinib data and launched an Adagene collaboration, creating clinical momentum. Valuation looks reasonable, but analyst downgrades and execution risks keep the stance neutral.
Apr 6, 2026